Kiniksa Pharmaceuticals International (NASDAQ:KNSA) Reaches New 52-Week High – Time to Buy?

Kiniksa Pharmaceuticals International, plc (NASDAQ:KNSA) shares hit a new 52-week high on Friday . The stock traded as high as $43.73 and last traded at $42.7640, with a volume of 103178 shares. The stock had previously closed at $42.00.

Wall Street Analysts Forecast Growth

KNSA has been the subject of several recent research reports. Wall Street Zen downgraded shares of Kiniksa Pharmaceuticals International from a “strong-buy” rating to a “buy” rating in a research note on Sunday, November 2nd. Citigroup boosted their target price on shares of Kiniksa Pharmaceuticals International from $45.00 to $50.00 and gave the company a “buy” rating in a report on Friday, October 17th. The Goldman Sachs Group increased their target price on Kiniksa Pharmaceuticals International from $45.00 to $55.00 and gave the stock a “buy” rating in a research report on Wednesday, October 29th. Zacks Research lowered Kiniksa Pharmaceuticals International from a “strong-buy” rating to a “hold” rating in a research note on Monday, October 6th. Finally, Wedbush restated an “outperform” rating and issued a $48.00 target price on shares of Kiniksa Pharmaceuticals International in a research note on Tuesday, December 2nd. Six investment analysts have rated the stock with a Buy rating and two have given a Hold rating to the company. According to MarketBeat.com, Kiniksa Pharmaceuticals International currently has a consensus rating of “Moderate Buy” and an average target price of $52.00.

Kiniksa Pharmaceuticals International Trading Up 2.5%

The firm has a market cap of $3.26 billion, a P/E ratio of 95.62 and a beta of 0.02. The company’s 50 day simple moving average is $40.11 and its 200-day simple moving average is $34.84.

Kiniksa Pharmaceuticals International (NASDAQ:KNSA) last posted its quarterly earnings data on Tuesday, October 28th. The company reported $0.23 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $0.31 by ($0.08). The business had revenue of $180.86 million during the quarter, compared to analysts’ expectations of $166.64 million. Kiniksa Pharmaceuticals International had a return on equity of 7.46% and a net margin of 6.01%.The business’s quarterly revenue was up 61.2% compared to the same quarter last year. During the same period in the previous year, the business posted ($0.18) EPS. On average, sell-side analysts anticipate that Kiniksa Pharmaceuticals International, plc will post -0.55 earnings per share for the current year.

Insider Activity at Kiniksa Pharmaceuticals International

In related news, CEO Sanj K. Patel sold 97,390 shares of the company’s stock in a transaction on Wednesday, October 22nd. The shares were sold at an average price of $38.83, for a total transaction of $3,781,653.70. Following the sale, the chief executive officer owned 111,794 shares of the company’s stock, valued at $4,340,961.02. This represents a 46.56% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, CFO Mark Ragosa sold 42,841 shares of the business’s stock in a transaction on Monday, December 8th. The shares were sold at an average price of $41.49, for a total transaction of $1,777,473.09. Following the transaction, the chief financial officer owned 31,086 shares in the company, valued at $1,289,758.14. This trade represents a 57.95% decrease in their position. The disclosure for this sale is available in the SEC filing. Insiders have sold 553,057 shares of company stock worth $21,582,372 in the last three months. Corporate insiders own 53.48% of the company’s stock.

Institutional Trading of Kiniksa Pharmaceuticals International

Hedge funds have recently added to or reduced their stakes in the business. EverSource Wealth Advisors LLC grew its position in shares of Kiniksa Pharmaceuticals International by 140.4% in the 2nd quarter. EverSource Wealth Advisors LLC now owns 911 shares of the company’s stock valued at $25,000 after buying an additional 532 shares during the last quarter. Corebridge Financial Inc. increased its holdings in shares of Kiniksa Pharmaceuticals International by 3.6% during the first quarter. Corebridge Financial Inc. now owns 15,979 shares of the company’s stock valued at $355,000 after acquiring an additional 549 shares in the last quarter. Martingale Asset Management L P grew its position in Kiniksa Pharmaceuticals International by 1.3% in the 1st quarter. Martingale Asset Management L P now owns 50,000 shares of the company’s stock valued at $1,111,000 after purchasing an additional 640 shares during the period. Mariner LLC increased its stake in Kiniksa Pharmaceuticals International by 5.8% during the 3rd quarter. Mariner LLC now owns 13,253 shares of the company’s stock valued at $515,000 after purchasing an additional 732 shares in the last quarter. Finally, USA Financial Formulas acquired a new position in Kiniksa Pharmaceuticals International during the third quarter worth $32,000. 53.95% of the stock is owned by hedge funds and other institutional investors.

About Kiniksa Pharmaceuticals International

Kiniksa Pharmaceuticals International, Inc is a biopharmaceutical company focused on discovering, acquiring and developing therapeutics for patients suffering from lifethreatening and debilitating immune-mediated diseases. Founded in 2013 and headquartered in Lexington, Massachusetts, Kiniksa applies a patient-centric approach to build a diversified portfolio of marketed medicines and clinical-stage candidates targeting inflammation and immunology. The company’s core mission is to address complex conditions with significant unmet medical needs by advancing both novel and differentiated therapies.

The company’s lead marketed product is Ilaris (canakinumab), an interleukin-1β blocker licensed for the treatment of cryopyrin-associated periodic syndromes, systemic juvenile idiopathic arthritis, adult-onset Still’s disease and Schnitzler syndrome.